Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. 詳細を表示
– Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion – – New preclinical data from...
– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia – –...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.51 | -10.625 | 4.8 | 4.88 | 4.16 | 165443 | 4.34017029 | CS |
4 | -0.12 | -2.72108843537 | 4.41 | 4.88 | 4.09 | 201816 | 4.43150741 | CS |
12 | 0.42 | 10.8527131783 | 3.87 | 4.98 | 3.56 | 308528 | 4.25490188 | CS |
26 | -8.56 | -66.6147859922 | 12.85 | 15.04 | 3.56 | 528980 | 7.08778466 | CS |
52 | -17.71 | -80.5 | 22 | 24 | 3.56 | 353474 | 9.01856045 | CS |
156 | -17.71 | -80.5 | 22 | 24 | 3.56 | 353474 | 9.01856045 | CS |
260 | -17.71 | -80.5 | 22 | 24 | 3.56 | 353474 | 9.01856045 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約